Actinogen Achieves Significant Results in Xanamem® Depression Trial
Monday, 12 August 2024, 06:05
Actinogen's Phase 2a Trial Results
Actinogen has announced a significant achievement in the field of depression treatment with its Xanamem® product. The recent Phase 2a clinical trial showed
- clinically meaningful and persistent improvements in depression symptoms.
- The trial examined the key secondary endpoint of MADRS (Montgomery-Åsberg Depression Rating Scale).
These findings indicate that Xanamem® achieved statistical superiority over placebo in enhancing patients' cognitive attention levels.
Conclusions and Future Implications
The results from this trial could pave the way for Xanamem® as a new treatment option for those suffering from depression, representing a considerable shift in potential therapeutic approaches.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.